Insmed Inc (INSM)vsSalarius Pharmaceuticals Inc (SLRX)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SLRX
Salarius Pharmaceuticals Inc
$0.84
+29.23%
HEALTHCARE · Cap: $4.92M
Smart Verdict
WallStSmart Research — data-driven comparison
SLRX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
SLRX
Avoid21
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SLRX
The strongest argument for SLRX centers on Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SLRX
The primary concerns for SLRX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while SLRX is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
SLRX generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 21/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Salarius Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, is focused on developing epigenetics-based cancer treatments. The company is headquartered in Houston, Texas.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?